News Image

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Provided By GlobeNewswire

Last update: May 9, 2025

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025

Read more at globenewswire.com

BOUNDLESS BIO INC

NASDAQ:BOLD (9/22/2025, 9:53:00 AM)

1.147

+0.01 (+0.61%)



Find more stocks in the Stock Screener

Follow ChartMill for more